Rhythm Pharmaceuticals - RYTM Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RYTM shares.
View RYTM analyst ratings or view top-rated stocks.

8 brokerages have issued 1-year target prices for Rhythm Pharmaceuticals' shares. Their RYTM share price forecasts range from $16.00 to $37.00. On average, they anticipate the company's stock price to reach $28.78 in the next year. This suggests a possible upside of 39.6% from the stock's current price.
View analysts price targets for RYTM or view top-rated stocks among Wall Street analysts.

Rhythm Pharmaceuticals' stock was trading at $9.98 at the start of the year. Since then, RYTM shares have increased by 106.5% and is now trading at $20.61.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our RYTM earnings forecast.

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) released its quarterly earnings data on Tuesday, August, 2nd. The company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.79) by $0.10. The business earned $9.07 million during the quarter, compared to analyst estimates of $21.65 million. Rhythm Pharmaceuticals had a negative net margin of 1,310.60% and a negative trailing twelve-month return on equity of 67.73%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), Kadmon (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT).

(RYTM) raised $100 million in an initial public offering (IPO) on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager.

Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."

Rhythm Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Primecap Management Co. CA (12.55%), Federated Hermes Inc. (8.67%), Goldman Sachs Group Inc. (6.23%), Assenagon Asset Management S.A. (1.37%), FMR LLC (1.10%) and Millennium Management LLC (0.96%). Insiders that own company stock include David P Meeker, Hunter C Smith, Joseph Shulman, Nithya Desikan, Pamela J Cramer, Ra Capital Management, LP, Todd Foley, William T Roberts and Yann Mazabraud.
View institutional ownership trends.

Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RYTM stock can currently be purchased for approximately $20.61.

Rhythm Pharmaceuticals (NASDAQ:RYTM) has a market capitalization of $1.16 billion and generates $3.15 million in revenue each year. The company earns $-69,610,000.00 in net income (profit) each year or ($3.49) on an earnings per share basis.

The company employs 140 workers across the globe.

Rhythm Pharmaceuticals' mailing address is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. The official website for the company is www.rhythmtx.com. The company can be reached via phone at (857) 264-4280, via email at hannah.deresiewicz@sternir.com, or via fax at 857-264-4299.